New Antibiotic Weapon Gets Funding in War on Superbugs

ALLSCHWIL, SWITZERLAND – April 09, 2026 – In a significant step forward in the global battle against antibiotic-resistant bacteria, Swiss biopharmaceutical company Basilea Pharmaceutica has secured an additional USD 6 million in funding to advance a promising new antibiotic that has just entered human clinical trials. The drug, BAL2420, represents a novel class of weapon aimed at some of the world's most dangerous superbugs.

The non-dilutive funding comes from CARB-X, a global non-profit partnership dedicated to accelerating antibacterial innovation. It will support the first-in-human Phase 1 clinical study for BAL2420, which began in March 2026. This development marks a critical milestone for a drug candidate that offers a new mode of action against deadly Gram-negative bacteria, a category of pathogens that has become notoriously difficult to treat.

The Looming Threat of a Silent Pandemic

While the world has been focused on viral pandemics, a quieter but equally devastating crisis has been escalating: antimicrobial resistance (AMR). The World Health Organization (WHO) and other global health bodies have long warned of this "silent pandemic." In 2019 alone, bacterial AMR was directly responsible for an estimated 1.27 million deaths worldwide—more than HIV/AIDS or malaria—and was associated with nearly 5 million deaths.

At the heart of this crisis are Gram-negative bacteria. These pathogens, which include well-known names like E. coli and K. pneumoniae, are protected by a tough outer membrane that makes them intrinsically resistant to many drugs. When these bacteria acquire resistance to multiple antibiotics, including last-resort treatments like carbapenems and colistin, they become multidrug-resistant "superbugs."

These superbugs are a primary cause of severe hospital-acquired infections, such as pneumonia, bloodstream infections, and complicated urinary tract infections. With the pipeline for new antibiotics running dangerously dry for decades, doctors are increasingly left with limited or no effective treatment options. The CDC and WHO have both designated carbapenem-resistant Enterobacteriaceae as urgent threats requiring new and effective treatments immediately.

A Novel Weapon in the Arsenal

Basilea's BAL2420 offers a new ray of hope by attacking these bacteria in a completely new way. It is a first-in-class LptA inhibitor, belonging to one of the very few novel classes of antibiotics currently in clinical development.

Instead of targeting pathways used by existing antibiotics, BAL2420 disrupts the construction of the bacteria's protective outer membrane. It specifically targets LptA, a crucial protein responsible for transporting lipopolysaccharide (LPS)—a key building block—to the outer membrane. By blocking this transport bridge, the drug effectively sabotages the bacteria's primary defense, leading to rapid cell death.

"BAL2420 offers a new mode of action with the potential to address significant unmet medical needs in the treatment of severe Gram-negative bacterial infections including those caused by multidrug-resistant bacteria," said Dr. Marc Engelhardt, Chief Medical Officer of Basilea, in a statement.

Because the mechanism is entirely new, it holds the potential to be effective against strains that have already evolved defenses against nearly every other antibiotic in the medical arsenal. Preclinical studies have shown BAL2420 to be potent and rapidly bactericidal against a range of high-priority Gram-negative pathogens.

Fueling Innovation Beyond the Market

The journey of a drug like BAL2420 from laboratory concept to clinical trial highlights a fundamental challenge in modern medicine: the broken economic model for antibiotic development. Creating a new antibiotic is scientifically difficult, time-consuming, and expensive. However, unlike drugs for chronic conditions, new antibiotics are used sparingly to preserve their effectiveness, making it difficult for developers to recoup their investment.

This market failure has caused many large pharmaceutical companies to exit the field, leaving a dangerous innovation gap. This is where organizations like CARB-X have become indispensable. Led by Boston University and funded by a global consortium of governments and foundations, CARB-X acts as a non-profit accelerator, providing critical non-dilutive funding to de-risk promising early-stage projects.

Since 2016, CARB-X has supported over 120 projects, playing a vital role in nurturing the fragile early-stage pipeline. The organization reports that it has supported 67% of the current Phase 1 clinical pipeline of non-traditional antibacterial therapeutics targeting WHO critical priority pathogens.

"Sustained funding and collaboration with innovative companies such as Basilea are critical to the development of novel antibacterial treatments that are of critical importance," commented Dr. Richard Alm, Interim Chief of Research and Development of CARB-X. The partnership with Basilea on BAL2420, which began in 2020, has successfully guided the project from an early "hit-to-lead" stage all the way to its current first-in-human study, demonstrating the power of this collaborative model.

From Lab to Clinic: Basilea's Strategic Push

For Basilea, the advancement of BAL2420 is a key part of its long-term strategy. Unlike a small startup, Basilea is a commercial-stage company with a proven track record of bringing anti-infective drugs to market, including the antifungal Cresemba and the antibiotic Zevtera. This experience in navigating the complex regulatory and commercial landscape for hospital-based drugs provides a strong foundation for the BAL2420 program.

The company strategically acquired the LptA antibiotics program, which includes BAL2420, from Spexis AG in early 2024, integrating a high-potential, novel-mechanism asset into its pipeline. The successful completion of preclinical studies and the initiation of the Phase 1 trial, supported by CARB-X, represent a significant return on that strategic decision.

The Phase 1 study will be the first test of BAL2420 in humans, designed to evaluate its safety, tolerability, and how it is processed by the body. The results will be a crucial first step in determining if the drug's impressive preclinical performance can be translated into a safe and effective treatment for patients suffering from life-threatening infections. As the trial progresses, the global health community will be watching closely, hopeful that this novel weapon may soon be ready for the front lines of the war against superbugs.